Screener
CRISPR Therapeutics CRSP Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by CRISPR Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The source filing: CRISPR Therapeutics’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 4:48 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-204188
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Purchases of marketable securities | (746,089) | (200,730) |
| Maturities of marketable securities | 192,759 | 186,181 |
| Sales of marketable securities | 147,706 | — |
| Net cash used in investing activities | (410,743) | (19,755) |
| Financing activities: | ||
| Proceeds from issuance of the Notes | 600,000 | — |
| Issuance costs and discounts associated with the Notes | (13,528) | — |
| (Payments) proceeds from issuance of common shares, net of issuance costs | (722) | 8,516 |
Item 1. Financial Statements
FAQ
- What is CRISPR Therapeutics's investing cash flow?
- CRISPR Therapeutics (CRSP) reported investing cash flow of -$410.74M in Q1 2026.
- How has CRISPR Therapeutics's investing cash flow changed year-over-year?
- CRISPR Therapeutics's investing cash flow decreased by 1979.2% year-over-year, from -$19.76M to -$410.74M.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.
Ask your AI about CRISPR Therapeutics's investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude